Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pjotr Knyazev

Metformin and Salinomycin as the Best Combination for the Eradication of NSCLC Monolayer Cells and Their Alveospheres (Cancer Stem Cells) Irrespective of EGFR, KRAS, EML4/ALK and LKB1 Status

Oncotarget

Oncology

2014

English

Salinomycin Co-Treatment Enhances Tamoxifen Cytotoxicity in Luminal a Breast Tumor Cells by Facilitating Lysosomal Degradation of Receptor Tyrosine Kinases

Oncotarget

Oncology

2016

English

Related publications

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

Journal of Thoracic Oncology

English

Fusion of EML4 and ALK Is Associated With Development of Lung Adenocarcinomas Lacking EGFR and KRAS Mutations and Is Correlated With ALK Expression

English

Targeted Photodynamic Therapy as Potential Treatment Modality for the Eradication of Colon Cancer and Colon Cancer Stem Cells

English

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

English

Roles of WNT/Β-Catenin Signaling in the Gastric Cancer Stem Cells Proliferation and Salinomycin Treatment

Cell Death and Disease

Molecular Neuroscience

English

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

European Journal of Cancer

Cancer Research

Oncology

2010

English

Effects of SMYD2-mediated EML4-ALK Methylation on the Signaling Pathway and Growth in Non-Small-Cell Lung Cancer Cells

English

Stem Cells and Cancer Stem Cells

2011

English

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Pjotr Knyazev

Metformin and Salinomycin as the Best Combination for the Eradication of NSCLC Monolayer Cells and Their Alveospheres (Cancer Stem Cells) Irrespective of EGFR, KRAS, EML4/ALK and LKB1 Status

Salinomycin Co-Treatment Enhances Tamoxifen Cytotoxicity in Luminal a Breast Tumor Cells by Facilitating Lysosomal Degradation of Receptor Tyrosine Kinases

Related publications

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

Fusion of EML4 and ALK Is Associated With Development of Lung Adenocarcinomas Lacking EGFR and KRAS Mutations and Is Correlated With ALK Expression

Targeted Photodynamic Therapy as Potential Treatment Modality for the Eradication of Colon Cancer and Colon Cancer Stem Cells

Clinical Evaluation of the Utility of a Liquid Biopsy (Circulating Tumoral Cells and ctDNA) to Determine the Mutational Profile (EGFR, KRAS, ALK, ROS1 and BRAF) in Advanced NSCLC Patients

Roles of WNT/Β-Catenin Signaling in the Gastric Cancer Stem Cells Proliferation and Salinomycin Treatment

The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer

Effects of SMYD2-mediated EML4-ALK Methylation on the Signaling Pathway and Growth in Non-Small-Cell Lung Cancer Cells

Stem Cells and Cancer Stem Cells

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC